2022-500408-22-00招募中3 期
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1).
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 16
- 主要终点
- Number of Participants With Adverse Events
研究概览
简要总结
The objective of this study is to assess the long-term safety, tolerability, and efficacy of risankizumab in subjects with moderate to severe plaque psoriasis who have completed participation in the preceding study (Study M19-977).
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Overall Trial
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •Participants who have completed participation in study M19-977 and who meet all eligibility criteria for participation in Study M19-973 will be allowed to enroll in study M19-973.
排除标准
- •Participants who have developed any discontinuation criteria as defined in Study M19-977.
结局指标
主要结局
Number of Participants With Adverse Events
Number of Participants With Adverse Events
次要结局
未报告次要终点
研究者
Global Clinical Trials Helpdesk
Scientific
Abbvie Deutschland GmbH & Co. KG
研究点 (16)
Loading locations...
相似试验
已完成
3 期
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms (OptIMMize-1)2023-504156-10-00Abbvie Deutschland GmbH & Co. KG72
招募中
3 期
An extension study to find out if multiple treatment cycles of rozanolixizumab are safe and work in children with myasthenia gravisGeneralized Myasthenia Gravis2022-502075-34-00UCB Biopharma7
招募中
2 期
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
招募中
3 期
A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease2022-501645-70-00Abbvie Deutschland GmbH & Co. KG208
招募中
1 期
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsUnresectable Locally Advanced or Metastatic Urinary Tract TumorsNCT07280832Shanghai JMT-Bio Inc.500